NCT01652144 is a Phase 2 clinical trial of AT7519M in Mantle Cell Lymphoma, sponsored by NCIC Clinical Trials Group.

Who is sponsoring NCT01652144?

NCT01652144 is sponsored by NCIC Clinical Trials Group.

What drugs are being tested in NCT01652144?

Interventions in NCT01652144: AT7519M.

What condition does NCT01652144 study?

NCT01652144 studies Mantle Cell Lymphoma.

Is NCT01652144 still recruiting?

NCT01652144 is currently completed. Last updated 4 August 2023.

Last reviewed 2023-08-04 · How we verify

NCT01652144

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Completed Phase 2 Last updated 4 August 2023

What this trial tests

Phase 2 trial testing AT7519M in Mantle Cell Lymphoma in 12 participants. Completed in 13 February 2015.

Timeline

14 September 2012

Primary endpoint
2 December 2014

13 February 2015

Quick facts

Lead sponsor	NCIC Clinical Trials Group
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	14 September 2012
Primary completion	2 December 2014
Estimated completion	13 February 2015
Sites	6 locations across Canada

Drugs / interventions tested

AT7519M — full drug profile →

Conditions studied

Mantle Cell Lymphoma — all drugs for Mantle Cell Lymphoma →

Sponsor

NCIC Clinical Trials Group

Who can join

18 and older, any sex, with Mantle Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out what effects a new drug AT7519M has on mantle cell lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of AT7519M

Trials testing the same drug.

NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed

Other recruiting trials for Mantle Cell Lymphoma

Currently open trials in the same condition.

NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06839053 — Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic L · Phase 2 · recruiting
NCT06357676 — Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · Phase 1, PHASE2 · recruiting
NCT06854003 — BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Fo · Phase 2 · recruiting

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed
NCT01331083 — A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01652144 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
Last refreshed: 4 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01652144.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing